Chen Y P, Wang H Y, Zou W Z
Chin Med J (Engl). 1989 Jul;102(7):510-5.
Primary mesangial proliferative glomerulonephritis without IgA deposition (non-IgA MsPGN) is one of the most common types of glomerular disease in China. In an attempt to investigate its clinical and pathological features, we reviewed 77 such cases from 380 patients with primary glomerulonephritis taken renal biopsies during 1980-1987. Prodromal upper respiratory tract infection occurred in 31 cases (40%). In immunofluorescence microscopy, prominent IgG granular deposits in mesangium were observed in 45 cases (58%). These features are quite different from those in western countries, indicating it might have different pathogenetic processes. According to the severity of mesangial lesions, the 77 cases were divided into 3 groups: mild (55 cases), moderate (14) and severe (8). In the patients with mild mesangial lesion and massive proteinuria, the therapeutic response to prednisone was similar to that in adult minimal change disease. In the moderate and severe groups, there was a significantly higher incidence of superimposed tubulo-interstitial lesions associated with hypertension, persistent renal insufficiency and a poor response to prednisone. This work showed non-IgA MsPGN covered about 20% of our primary glomerulopathy, which may be related to a higher incidence of infection. It was suggested that minimal change nephrotic syndrome, inspite of the variety of immunoglobulin mesangium deposits, could be treated as a single disease entity, and light microscopy is most important in offering prognostic information.
原发性系膜增生性肾小球肾炎伴IgA无沉积(非IgA系膜增生性肾小球肾炎)是中国最常见的肾小球疾病类型之一。为了研究其临床和病理特征,我们回顾了1980 - 1987年间380例接受肾活检的原发性肾小球肾炎患者中的77例此类病例。前驱上呼吸道感染发生在31例(40%)。在免疫荧光显微镜检查中,45例(58%)观察到系膜中有显著的IgG颗粒沉积。这些特征与西方国家的不同,表明其发病机制可能不同。根据系膜病变的严重程度,将77例分为3组:轻度(55例)、中度(14例)和重度(8例)。在轻度系膜病变且有大量蛋白尿的患者中,对泼尼松的治疗反应与成人微小病变病相似。在中度和重度组中,叠加肾小管间质病变的发生率显著更高,伴有高血压、持续性肾功能不全以及对泼尼松反应不佳。这项研究表明非IgA系膜增生性肾小球肾炎约占我们原发性肾小球病的20%,这可能与感染发生率较高有关。有人提出,尽管免疫球蛋白系膜沉积多样,但微小病变肾病综合征可作为单一疾病实体治疗,而光镜检查在提供预后信息方面最为重要。